Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston blog main
boston top stories
deals
5
×
life sciences
5
×
national blog main
national top stories
new york blog main
new york top stories
novartis
5
×
alzheimer's disease
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
amgen
biogen
cancer
cancer immunotherapy
diagnostics
drug prices
eli lilly
gilead sciences
What
drug
5
×
bio
roundup
acquisitions
biggest
ceo
companies
company
new
price
acquire
agreed
albert
alzheimer’s
approval
billion
biogen’s
biopharmaceutical
bourla
brings
build
buy
cash
cholesterol
company’s
compound
convo
crispr
daniel
deal
debut
different
dyne’s
earlier
fail
failures
fda
future
gene
gilead
Language
unset
unknown
Current search:
drug
×
biotech
×
novartis
×
" life sciences "
×
deals
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More